Last €1.85 EUR
Change Today +0.049 / 2.72%
Volume 10.7K
WL6 On Other Exchanges
Symbol
Exchange
Xetra
OTC US
As of 11:36 AM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

wilex ag (WL6) Snapshot

Open
€1.87
Previous Close
€1.80
Day High
€1.93
Day Low
€1.84
52 Week High
01/9/14 - €6.28
52 Week Low
12/2/14 - €1.78
Market Cap
14.5M
Average Volume 10 Days
7.4K
EPS TTM
€-0.59
Shares Outstanding
7.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for WILEX AG (WL6)

Related News

No related news articles were found.

wilex ag (WL6) Related Businessweek News

No Related Businessweek News Found

wilex ag (WL6) Details

WILEX AG, a biopharmaceutical company, is focuses on the research, development, manufacture, approval, and marketing of drugs and diagnostic agents in the field of oncology. The company operates in three segments: Therapeutics (Rx), Diagnostics (Dx), and Customer Specific Research (Cx). Its primary product candidates based on antibodies and small-molecule compounds comprise REDECTANE, an imaging diagnostic candidate that has completed Phase III clinical trials for the treatment of renal masses; and MESUPRON, which has completed Phase clinical trials for the treatment of pancreatic and breast cancer. The company also provides customer specific contract services related to a technology platform for therapeutic antibody drug conjugates; and preclinical research services in the field of cancer, as well as inflammatory and autoimmune diseases. WILEX AG has a strategic alliance with UCB Pharma S.A. (UCB) to develop UCB’s preclinical oncological portfolio comprising two small-molecule programs and three antibody programs. The company was formerly known as WILEX Biotechnology GmbH and changed its name to WILEX AG in February 2001. WILEX AG was founded in 1997 and is headquartered in Munich, Germany.

49 Employees
Last Reported Date: 10/16/14
Founded in 1997

wilex ag (WL6) Top Compensated Officers

Chief Financial Officer and Member of the Exe...
Total Annual Compensation: €287.2K
Head of Research & Development and Member of ...
Total Annual Compensation: €245.8K
Compensation as of Fiscal Year 2013.

wilex ag (WL6) Key Developments

Wilex AG Presents at 4th Annual Berenberg 1 - 1 Symposium @ German Equity Forum, Nov-25-2014

Wilex AG Presents at 4th Annual Berenberg 1 - 1 Symposium @ German Equity Forum, Nov-25-2014 . Venue: Maritim Hotel, Theodor-Heuss-Allee 3, 60486 Frankfurt am Main, Germany.

Wilex AG Reports Consolidated Earnings Results for the First Nine Months Ended August 31, 2014; Revised Earnings Guidance for the Full Fiscal Year 2014

Wilex AG reported consolidated earnings results for the first nine months ended August 31, 2014. For the first nine months of the 2014, generated sales revenue and income totaling was EUR 6.1 million, down 46% on EUR 11.4 million in the previous year. This figure includes sales revenue of EUR 2.8 million compared to EUR 10.1 million in the previous year generated in the Cx and Rx segments. In line with planning, the Dx segment did not post any sales revenue. The previous year's figure was mainly a reflection of individual components of the terminated licence agreement with Prometheus for RENCAREX(R). At EUR 3.3 million, other income was significantly higher than the prior-year figure (EUR 1.3 million) and mainly stemmed from UCB's waiver of the loan repayment and the reversal through profit or loss of provisions that were not required in the amounts planned. Furthermore, both the Rx segment and the Cx segment received grants from the Federal Ministry of Education and Research (BMBF) for research projects. Operating loss was EUR 1.712 million compared to EUR 3.893 million for the same period last year. Loss before taxes was EUR 1.763 million compared to EUR 3.956 million for the same period last year. Net loss for the period was EUR 1.811 million or EUR 0.07 per share compared to EUR 3.956 million or EUR 0.13 per share for the same period last year. Cash flow used in operating activities was EUR 6.168 million compared to EUR 13.499 million for the same period last year. The company revised earnings guidance for the full fiscal year 2014. For the fiscal year 2014, the company now expects sales revenue and other income of EUR 6.0 million to EUR 7.5 million compared to previous guidance of EUR 3.0 million to EUR 4.0 million. Operating loss will be in the range of EUR 2.0 million to EUR 3.5 million compared to previous guidance of EUR 4.5 million to EUR 7.5 million.

Wilex AG, Nine Months 2014 Earnings Call, Oct 15, 2014

Wilex AG, Nine Months 2014 Earnings Call, Oct 15, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
WL6:GR €1.85 EUR +0.049

WL6 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for WL6.
View Industry Companies
 

Industry Analysis

WL6

Industry Average

Valuation WL6 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.7x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact WILEX AG, please visit www.wilex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.